Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-02-28
2009-12-08
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07629329
ABSTRACT:
The present invention is directed to compositions having an effective amount of Adenosine Triphosphate (“ATP”) sufficient to effect intracellular and extracellular concentrations of ATP in a mammal to improve anaerobic exercise capacity by increasing muscle size and/or strength and methods for using the same. Preferably, a gastric acid secretion inhibitory coating is applied to the effective amount of ATP in a manner that protects the ATP from degradation by gastric juices. ATP compositions of the present invention may be administered in nutraceutical or functional food dosage forms, including oral and non-oral delivery forms. In addition, the effective amount of ATP maybe combined with amino acids, botanicals, functional foods, herbals, nucleotides, nutraceuticals, nutrients, pharmaceuticals, proteins, and/or vitamins in an effort to enhance the targeted activity of the composition.
REFERENCES:
patent: 3819830 (1974-06-01), Yoshimura
patent: 4880918 (1989-11-01), Rapaport
patent: 4923851 (1990-05-01), Carniglia
patent: 5017564 (1991-05-01), Makino et al.
patent: 5023244 (1991-06-01), Goto et al.
patent: 5030623 (1991-07-01), Gruber
patent: 5049372 (1991-09-01), Rapaport
patent: 5055304 (1991-10-01), Makino et al.
patent: 5227371 (1993-07-01), Rapaport
patent: 5332579 (1994-07-01), Umbdenstock
patent: 5391550 (1995-02-01), Carniglia et al.
patent: 5547942 (1996-08-01), Rapaport
patent: 5616564 (1997-04-01), Rapaport et al.
patent: 5707971 (1998-01-01), Fahy
patent: 5767159 (1998-06-01), Hultman et al.
patent: 5981601 (1999-11-01), Nagley et al.
patent: 6100287 (2000-08-01), Stevens et al.
patent: 6143784 (2000-11-01), Greenhaff et al.
patent: 6159942 (2000-12-01), St. Cyr et al.
patent: 6159943 (2000-12-01), Butler et al.
patent: 6184214 (2001-02-01), Dogadina et al.
patent: 6296892 (2001-10-01), Elseviers et al.
patent: 6299857 (2001-10-01), Elmaleh et al.
patent: 6335436 (2002-01-01), Rapaport et al.
patent: 6399661 (2002-06-01), Golini
patent: 6429198 (2002-08-01), St. Cyr et al.
patent: 6440660 (2002-08-01), Barker, Jr. et al.
patent: 6525027 (2003-02-01), Vazquez et al.
patent: 6723737 (2004-04-01), Rapaport
patent: 7056529 (2006-06-01), Ehringer et al.
patent: 2002/0052336 (2002-05-01), Yerxa et al.
patent: 2002/0072501 (2002-06-01), Cyr et al.
patent: 1234234 (1999-11-01), None
patent: WO 97/25972 (1997-07-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 00/25758 (2000-05-01), None
patent: WO 01/28528 (2001-04-01), None
patent: WO 01/45691 (2001-06-01), None
“More Strength..”, product flyer for Adenergy with Peak ATP, Jan. 2004.
Prodcut Description for “Adenergy with Peak ATP” from the website: www.bodyconcept.com/family/1339/display.html.
Mary L. Ellsworth, “Red Blood Cell-Derived ATP as a Regulator of Skeletal Muscle Perfusion,” Medicine and Science in Sports and Exercise, 2004, pp. 35-41.
Kim Schoenhals, “Cognitive Function”, Natural Products Industry Insider, Feb. 2, 2004 , pp. 18-25.
“More Strength, More Energy, More Lean Muscle,” product advertisement for optimumnutrition.com regarding ADENERGY™ with Peak ATP™, Jan. 2004.
Pieter C. Dagnelie et al., “Promising Effects of Adenosine Triphosphate Infusion on Nutritional Status and Quality of Life in Advanced Non-Small-Cell Lung Cancer: a Randomized Clinical Trial,”Drug Development Research, 2003, 59:146-151.
Randy S. Sprague et al., “Extracellular ATP Signaling in the Rabbit Lung: Erythrocytes as Determinants of Vascular Resistance,”Am J. Phvsiol Heart Circ Physiol, 2003, 285: H693-H700.
Hendrik J. Agteresch, et al., “Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial, ”Journal of Clinical Oncology, vol. 20, No. 2, Jan. 15, 2002, pp. 371-378.
Josè Gonzàlez-Alonso et al., “Erythrocyte and the Regulation of Human Skeletal Muscle Blood Flow and Oxygen Delivery,”Circulation Research, Nov. 29, 2002, pp. 1046-1055.
Susanne Leij-Halfwerk, et al., “Adenosine Triphosphate Infusion Increases Liver Energy Status in Advanced Lung Cancer Patients: An In Vivo 31P Magnetic Resonance Spectroscopy Study,”Hepatology, Feb. 2002, pp. 421-423.
H. J. Agteresch et al., “Pharmacokinetics of Intravenous ATP in Cancer Patients”,Eur J. Clin Pharmacol, (2000) vol. 56, pp. 49-55.
Ketty Kichenin et al., “Chronic Oral Administration of ATP Modulates Nucleoside Transport and Purine Metabolism in Rats,”The Journal of Pharmacology and Experimental Therapeutics(U.S.A. 2000), vol. 294, No. 1, pp. 126-133.
Ketty Kichenin, et al., “Cardiovascular and Pulmonary Response to Oral Administration of ATP in Rabbits,”J. Appl. Pysiol, 2000, pp. 1962-1968.
Kato M, et al., “Adenosine 5′—Triphosphate Induced Dilation of Human Coronary Microvessels in Vivo,”Intern Med.1999, vol. 38, No. 4, pp. 324-329.
Arakawa A, et al., “Preparation of Liposome-Encapsulating Adenosine Triphosphate,”Tohoku J Exp. Med.Jan. 1998, vol. 184, No. 1, pp. 39-47.
Maresh CM, et al., “Dietary Supplementation and Improved Anaerobic Performance,”International Journal of Sport NutritionDec. 1994; vol. 4, No. 4, pp. 387-397.
GX Xu, et al., “Studies on the Preparation of Adenosine Triphosphate (ATP) Liposomes” 1989, vol. 24, No. 2, pp. 133-138.
T. Forrester et al., “Effect of Adenosine Triphosphate and Some Derivatives on Cerebral Blood Flow and Metabolism”,J. Physiol.(1979), vol. 296, pp. 343-355.
“Intestinal Absorption of Adenosine Triphosphate,”Nutritional Reviews, vol. 36, No. 10, Oct. 1978, pp. 309-311.
Kono H, et al., “Intestinal Absorption of ATP in Healthy Subjects,”Naika1971, vol. 28, No. 5, pp. 943-945.
Myron H. Steinberg, “Adenosine-5-Monophosphate in Venous Insufficiency,”Angiology, 1958; 9:154-161.
Raymond Boller et al., “Therapeutic Action of Muscle Adenylic Acid on Ulcers and Dermatitis Associated with Varicose or Phlebitic Veins; Follow Up Report,”Angiology, 1952, 3: 260-266.
John W. Daly, “Adenosine Receptors: Targets for Future Drugs,” Journal of Medicinal Chemistry, vol. 25, No. 3, Mar. 1982, pp. 197-207.
Hynson Richard B.
Lee Steve S.
Zhou Joe
Marshall & Gerstein & Borun LLP
McIntosh, III Traviss C
TSI Health Sciences, Inc.
LandOfFree
Method for increasing muscle mass and strength through... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing muscle mass and strength through..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing muscle mass and strength through... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059667